|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The <sup>18</sup>F-MAPP imaging detected sites of elevated MPO activity in living mice embedded with human MPO and in mice induced with chemical inflammation or myocardial infarction.
|
31123149 |
2019 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Myeloperoxidase (MPO) is a highly abundant protein within the neutrophil that is associated with lipoprotein oxidation, and increased plasma MPO levels are correlated with poor prognosis after myocardial infarct.
|
30889221 |
2019 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These therapeutic effects are mainly associated with the inhibition of LDL cholesterol (anti-atherosclerosis), inhibition of NF-κB (anti-cardiac hypertrophy), inhibition of MPO activity (anti-myocardial infarction), reduction in plasma glucose and glycated haemoglobin level (anti-diabetes), reduction of inflammatory markers (anti-inflammatory) and the inhibition of ROS generation (antioxidant).
|
28864169 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of myeloperoxidase on HDL function in myocardial infarction.
|
29356689 |
2018 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We identified a rapid increase of Reg3β, CRP and MPO expression in cardiac tissue and serum within the first 24 h after MI.
|
29544958 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, matrix metalloproteinase-8 concentration was associated with the risk for a coronary artery disease event, myocardial infarction and death, and myeloperoxidase concentration with the risk for cardiovascular disease events, stroke and death.
|
28429955 |
2017 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The associations of MPO/HDLp with incident ASCVD (first non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or CVD death) and total CVD were assessed in Cox proportional-hazards models adjusted for traditional risk factors.
|
28645072 |
2017 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It was shown that MPO levels were increasing in patients after myocardial infarct event but there were no effect of MPO -463 G/A polymorphism on MPO levels.
|
20568015 |
2011 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diabetic patients in this post-myocardial infarction cohort with UCP2 -866 AA/GA genotype have poorer survival and higher myeloperoxidase levels than their GG counterparts.
|
19527523 |
2009 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The A allele of the MPO -129G/A promoter polymorphism is associated with a reduced MI risk in women.
|
19543083 |
2009 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction.
|
18777087 |
2009 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
LHGDN |
Elevated levels of myeloperoxidase, white blood cell count and 3-chlorotyrosine in Taiwanese patients with acute myocardial infarction.
|
18314009 |
2008 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
LHGDN |
The present data separate inflammatory effects on infarct size and LV remodeling and demonstrate that MPO-generated oxidants do not significantly affect tissue necrosis after MI but rather have a profound adverse effect on LV remodeling and function.
|
16267254 |
2005 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction.
|
12615902 |
2003 |